NLSUI OPAC header image

Patent and competition interface through the prism of pharmaceutical sector : a comparative approach of US, EU and India

By: Contributor(s): Publication details: BangaloreBangalore NLSIU 2020Description: 91 p. ; 25 cmOnline resources:
Contents:
TABLE OF CONTENTS ACKNOWLEDGEMENT ; ABBREVIATIONS ; LIST OF CASES ; CHAPTER 1 ; INTRODUCTION ; CHAPTER 2 ; COMPETITION & ANTI-TRUST ISSUES IN THE PHARMACEUTICAL INDUSTRY WITHIN US ; 2.1 LEGAL FRAMEWORK OF ANTI-TRUST LAWS ; 2.2 PATENT LINKAGE SYSTEM IN US: REVISITING HATCH WAXMAN ACT ; THE GENERIC INCENTIVES ; THE INNOVATOR INCENTIVES ; 2.3 TYPE OF ANTI-TRUST CASES LEADING TO INTERFACE IN THE PHARMACEUTICAL INDUSTRY ; 2.3.1 CASES OF MONOPOLIZATION ; 2.3.2 THE INNOVATOR MARKET DOCTRINE & MERGERS ; 2.3.3 MERGERS IN THE PHARMACEUTICAL INDUSTRY ; 2.3.4 POTENTIAL COMPETITION MERGERS ; 2.4 THE EVERGREENING DEBATE IN US ; 2.5 PRODUCT HOPPING; 2.5.1 STANCE ON PRODUCT HOPPING ; 2.6 AGREEMENTS NOT TO COMPETE: PAY FOR DELAY ; 2.7 CONCLUSIONS & IMPLICATION ON DEVELOPING & LEAST DEVELOPED COUNTRIES ; CHAPTER 3 ; PHARMACEUTICAL BUSINESS STRATEGIES: COMPETITION BETWEEN ORIGINATOR & GENERIC COMPANIES WITHIN EU ; 3.1 PATENT LINKAGE SYSTEM IN EU ; 3.2 EUROPEAN PATENT SYSTEM: REQUIREMENTS FOR PATENTABILITY ; 3.3 EUROPEAN PATENT CONVENTION ; 3.4 PATENTABILITY REQUIREMENTS ; 3.4.1 TECHNICAL CHARACTER ; 3.4.2 NOVELTY ; 3.4.3 INVENTIVE STEP ; 3.4.4. INDUSTRIAL APPLICABILITY ; 3.5 SUPPLEMENTARY PROTECTION CERTIFICATE ; 3.6 COMPETITION LAW IN EU ; 3.6.1 THE CONCEPT OF ABUSE OF DOMINANT & MONOPOLY POSITION ; 3.6.2 DOMINANCE OF AN UNDERTAKING WITHIN THE SUBSTANTIAL PART OF THE MARKET ; 3.6.3 WHAT CONSTITUTES ABUSE OF DOMINANCE ; 3.7 APPLIED PATENT STRATEGIES DURING THE DRUG LIFE CYCLE BY THE INNOVATORS & COMPETITION INTERFACE ; 3.7.1 SECOND GENERATION OR FOLLOW ON DRUGS & INFLUENCING MEDICAL FRATERNITY ; 3.7.2 PATENT CLUSTERS ; 3.7.3 DIVISIONAL PATENT APPLICATION ; 3.7.4 PATENT LITIGATION ; 3.7.5. DEVELOPMENT OF PATENT PORTFOLIO ; 3.8 THE ASTRAZENECA CASE ; 3.9 CONCLUSIVE ANALYSIS OF JUDGMENT ; 3.10 CONCLUSION OF STRATEGIES LEGALITY ; CHAPTER 4 ; DETERMINATION OF ANTI COMPETITIVE PRACTICES REGARDING PATENT ABUSE & PATENT LINKAGE SYSTEM IN INDIA ; 4.1 THE STANCE OF INDIAN JUDICIARY ON THE INTRODUCTION OF PATENT LINKAGE SYSTEM IN INDIA ; 4.2 PATENT EVERGREENING ; 4.3 IMPORTANCE OF RESEARCH & DEVELOPMENT FOR DYNAMIC PHARMACEUTICAL INDUSTRY ; 4.4 LEGAL FRAMEWORK ON RIGHT TO HEALTH & ACCESS TO MEDICINES ; 4.4.1 CONTOURS OF RIGHT TO HEALTH IN INDIA ; 4.4.2 TRIPS PERSPECTIVE OF PATENT SYSTEM & ESSENTIAL MEDICINES; 4.5 INDIAN APPROACH TO COMPETITION LAW & PHARMACEUTICAL INVENTIONS ; 4.6 COMPARATIVE ANALYSIS OF US, EU & INDIA ; 4.7 CONCLUSION ; CHAPTER 5 ; CONCLUSION & SUGGESTIONS ; BIBLIOGRAPHY .
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Status Barcode
Dissertation . Not for loan LLM830

TABLE OF CONTENTS ACKNOWLEDGEMENT ; ABBREVIATIONS ; LIST OF CASES ; CHAPTER 1 ; INTRODUCTION ; CHAPTER 2 ; COMPETITION & ANTI-TRUST ISSUES IN THE PHARMACEUTICAL INDUSTRY WITHIN US ; 2.1 LEGAL FRAMEWORK OF ANTI-TRUST LAWS ; 2.2 PATENT LINKAGE SYSTEM IN US: REVISITING HATCH WAXMAN ACT ; THE GENERIC INCENTIVES ; THE INNOVATOR INCENTIVES ; 2.3 TYPE OF ANTI-TRUST CASES LEADING TO INTERFACE IN THE PHARMACEUTICAL INDUSTRY ; 2.3.1 CASES OF MONOPOLIZATION ; 2.3.2 THE INNOVATOR MARKET DOCTRINE & MERGERS ; 2.3.3 MERGERS IN THE PHARMACEUTICAL INDUSTRY ; 2.3.4 POTENTIAL COMPETITION MERGERS ; 2.4 THE EVERGREENING DEBATE IN US ; 2.5 PRODUCT HOPPING; 2.5.1 STANCE ON PRODUCT HOPPING ; 2.6 AGREEMENTS NOT TO COMPETE: PAY FOR DELAY ; 2.7 CONCLUSIONS & IMPLICATION ON DEVELOPING & LEAST DEVELOPED COUNTRIES ; CHAPTER 3 ; PHARMACEUTICAL BUSINESS STRATEGIES: COMPETITION BETWEEN ORIGINATOR & GENERIC COMPANIES WITHIN EU ; 3.1 PATENT LINKAGE SYSTEM IN EU ; 3.2 EUROPEAN PATENT SYSTEM: REQUIREMENTS FOR PATENTABILITY ; 3.3 EUROPEAN PATENT CONVENTION ; 3.4 PATENTABILITY REQUIREMENTS ; 3.4.1 TECHNICAL CHARACTER ; 3.4.2 NOVELTY ; 3.4.3 INVENTIVE STEP ; 3.4.4. INDUSTRIAL APPLICABILITY ; 3.5 SUPPLEMENTARY PROTECTION CERTIFICATE ; 3.6 COMPETITION LAW IN EU ; 3.6.1 THE CONCEPT OF ABUSE OF DOMINANT & MONOPOLY POSITION ; 3.6.2 DOMINANCE OF AN UNDERTAKING WITHIN THE SUBSTANTIAL PART OF THE MARKET ; 3.6.3 WHAT CONSTITUTES ABUSE OF DOMINANCE ; 3.7 APPLIED PATENT STRATEGIES DURING THE DRUG LIFE CYCLE BY THE INNOVATORS & COMPETITION INTERFACE ; 3.7.1 SECOND GENERATION OR FOLLOW ON DRUGS & INFLUENCING MEDICAL FRATERNITY ; 3.7.2 PATENT CLUSTERS ; 3.7.3 DIVISIONAL PATENT APPLICATION ; 3.7.4 PATENT LITIGATION ; 3.7.5. DEVELOPMENT OF PATENT PORTFOLIO ; 3.8 THE ASTRAZENECA CASE ; 3.9 CONCLUSIVE ANALYSIS OF JUDGMENT ; 3.10 CONCLUSION OF STRATEGIES LEGALITY ; CHAPTER 4 ; DETERMINATION OF ANTI COMPETITIVE PRACTICES REGARDING PATENT ABUSE & PATENT LINKAGE SYSTEM IN INDIA ; 4.1 THE STANCE OF INDIAN JUDICIARY ON THE INTRODUCTION OF PATENT LINKAGE SYSTEM IN INDIA ; 4.2 PATENT EVERGREENING ; 4.3 IMPORTANCE OF RESEARCH & DEVELOPMENT FOR DYNAMIC PHARMACEUTICAL INDUSTRY ; 4.4 LEGAL FRAMEWORK ON RIGHT TO HEALTH & ACCESS TO MEDICINES ; 4.4.1 CONTOURS OF RIGHT TO HEALTH IN INDIA ; 4.4.2 TRIPS PERSPECTIVE OF PATENT SYSTEM & ESSENTIAL MEDICINES; 4.5 INDIAN APPROACH TO COMPETITION LAW & PHARMACEUTICAL INVENTIONS ; 4.6 COMPARATIVE ANALYSIS OF US, EU & INDIA ; 4.7 CONCLUSION ; CHAPTER 5 ; CONCLUSION & SUGGESTIONS ; BIBLIOGRAPHY .